


# Real-World US Optum Claims Database Study of Pre- and Post-Relapse Costs and Health Care Resource Utilization in Patients With High-Risk Localized or Locally Advanced Prostate Cancer Who Relapsed

## Supplementary Material

**Uwe Siebert<sup>1</sup>, Anders Bjartell<sup>2</sup>, Sandhya Nair<sup>3</sup>, Xiwu Lin<sup>4</sup>, Francesco De Solda<sup>5</sup>, Ravi Potluri<sup>6</sup>,  
Sharon A McCarthy<sup>7</sup>, Suneel D Mundle<sup>7</sup>, James McCallion<sup>5</sup>, Beate Jahn<sup>1</sup>**

<sup>1</sup>UMIT TIROL – University for Health Sciences and Technology, Hall in Tirol, Tirol, Austria; <sup>2</sup>Skåne University Hospital, Lund University, Malmö, Sweden; <sup>3</sup>Janssen Pharmaceutica NV, Beerse, Belgium; <sup>4</sup>Janssen Global Services, Horsham, PA, USA; <sup>5</sup>Janssen Global Services, Raritan, NJ, USA; <sup>6</sup>Putnam Associates, HEOR & RWE, New York, NY, USA; <sup>7</sup>Janssen Research & Development, Raritan, NJ, USA

# Supplementary Figure 1: Mean (95% CI) post-progression costs with and without censoring for patients who started with RP (A) and RT (B)



AS estimator is without censoring.  
AS, available sample; BT, Bang and Tsiatis's; CC, complete case; RP, radical prostatectomy; RT, radiotherapy.

# Supplementary Table 1: Baseline characteristics for patients starting with RP and RT

	Starting with RP (n=4938)	Starting with RT (n=3236)
<b>Age at HR-LPC/LAPC</b>		
Mean (SD)	65.4 (7.56)	72.4 (6.96)
Median [Min, Max]	67.0 [30.0, 90.0]	73.0 [41.0, 90.0]
<b>CCI at LAPC, n (%)</b>		
0	3447 (69.8)	1765 (54.5)
1	652 (13.2)	574 (17.7)
2	601 (12.2)	504 (15.6)
3	135 (2.7)	213 (6.6)
4	103 (2.1)	180 (5.6)
<b>Race, n (%)</b>		
White	3667 (74.3)	2296 (71.0)
African American	554 (11.2)	439 (13.6)
Hispanic	402 (8.1)	303 (9.4)
Asian	114 (2.3)	61 (1.9)
Other/Unknown	201 (4.1)	137 (4.2)
<b>Region, n (%)</b>		
South	1911 (38.7)	1317 (40.7)
Midwest	1417 (28.7)	684 (21.1)
West	1111 (22.5)	820 (25.3)
Northeast	488 (9.9)	410 (12.7)
Other/Unknown	11 (0.2)	5 (0.2)

CCI, Charlson Comorbidity Index; LAPC, locally advanced prostate cancer.

# Supplementary Table 2: Health care resource utilization during pre- and post-progression period

HCRU per-patient per-month	Unadjusted, mean				Adjusted, mean (95% CI)			
	Starting with RP		Starting with RT		Starting with RP		Starting with RT	
	Pre n=4938	Post n=4938	Pre n=3236	Post n=3236	Pre n=4938	Post n=4938	Pre n=3236	Post n=3236
<b>Outpatient visits per patient who had ≥ 1 visit</b>	1.58	2.24	2.95	2.44	1.21 (1.15-1.29)	1.98 (1.87-2.09)	2.50 (2.30-2.73)	1.89 (1.70-2.10)
<b>ER visits</b> ER visits per patient who had ≥ 1 visit	0.11	0.08	0.09	0.13	0.11 (0.09-0.13)	0.08 (0.07-0.09)	0.12 (0.10-0.16)	0.12 (0.09-0.15)
<b>Lab visits</b> Lab visits per patient who had ≥ 1 visit	0.50	0.45	0.51	0.63	0.44 (0.41-0.46)	0.42 (0.39-0.45)	0.46 (0.41-0.51)	0.56 (0.49-0.63)
<b>Hospital stay</b> Aggregate LOS per patient in months who had ≥ 1 hospitalization	0.29	0.36	0.41	0.76	0.22 (0.17-0.28)	0.26 (0.17-0.41)	0.30 (0.19-0.47)	0.51 (0.34-0.76)

ER, emergency room; HCRU, health care resource utilization; LOS, length of stay.